WHY TETRA BIO-PHARMA?
- Only pharmaceutical company to have clinical studies for smoked marijuana;
- Signed a letter of intent with a major player of the healthcare specialty industry
- Will benefit from the intellectual property created within the cannabis health research Chair from the University of New Brunswick
- Company is financially sound, with enough cash to pay for the $1.2Â million Phase III clinical trials of PPP001.
- Filing a clinical trial application in the coming weeks to therapeutic products directorate to initiate its Phase 3 clinical trial of PPP001 in terminal cancer patient
- Focused on expanding commercialization partnerships internationally for product pipeline – Interest has been shown from the USA, Germany, Ireland, Brazil and Mexico;
- Initial demand forecasted in New Brunswick for PPP001 using the ACMPR license is more than expected